novel coronavirus pneumonia (NCP) is a new type of respiratory infectious disease. Since December 2019, NCP patients have been discovered one after another in Wuhan, Hubei Province, China. With the spread of the epidemic, such cases have also been discovered in other parts of China and abroad. In the practice of first-line clinicians, nearly 20% of NCP patients have coagulation dysfunction, and almost all severe and critical patients have coagulation dysfunction[1,2]。 Acute inflammatory response caused by severe infection or sepsis can affect the coagulation and fibrinolysis system through various ways, including the decrease of circulating protein C and antithrombin-Ⅲ levels, the upregulation of plasminogen activator inhibitor-1 levels and other factors, which eventually lead to the activation of coagulation cascade and the inhibition of fibrinolysis process, thus promoting thrombosis. In some NCP patients, the disease suddenly deteriorates, the D-dimer is significantly increased, and even sudden death occurs during the progression of the disease. In this regard, special attention should be paid to whether pulmonary thromboembolism (PTE) occurs after deep vein thrombosis (DVT) is shed. It is suggested that in the process of prevention, control and treatment of NCP, attention should be paid to the assessment of the risk of venous thromboembolism (VTE), and effective prevention should be implemented for high-risk patients. Those with sudden clinical manifestations such as oxygenation deterioration, respiratory distress and blood pressure drop should be more alert to the occurrence of PTE and give corresponding treatment in time.
